arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

CytoDyn Inc.

CYDY
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
24 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
67
Health
Good
Bullish
auto_awesome

Analytical Summary

CytoDyn Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 54.0% ↗
FCF / Share $-0.01 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.35
info Valuation on last close.

24-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$266.00K
— —
Net Income Profit after all expenses
$-42.70M
↓ -1240.2% —
FCF / Share Free cash flow per share
$-0.01
↓ -84.1% —
Long-Term Debt Long-term obligations
$38.34M
↓ -15.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↓
92
Financial Health →
52
Cash Quality ↑
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 24 years · 72 quarters